Q2 2026 13F · SEC CIK 1599882

Rhenman & Partners Asset Management AB

Hedge fundFiled 2026-08-13 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $1.1B
Reported positions: 99
Top holdings a year, 3 yrs: +8.9%
Average holding period: 4.9 yrs

Rhenman & Partners Asset Management AB is a hedge fund that reported 99 positions worth $1.1B in its Q2 2026 13F, filed 2026-08-13. Its largest holdings were Unitedhealth Group Inc (UNH, 3.7%), Cvs Health Corp (CVS, 2.7%), Astrazeneca PLC (AZN, 2.7%). A portfolio copying its top holdings returned 8.9% a year over the last 3 years, against 20.4% for the S&P 500.

Rhenman & Partners Asset Management AB holdings largest 50 of 99 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Rhenman & Partners Asset Management AB 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
UNHUnitedhealth Group Inc	3.7%	1.5%	93,600	+105.7%	$38.9M
CVSCvs Health Corp	2.7%	3.0%	279,374	-17.0%	$28.9M
AZNAstrazeneca PLC	2.7%	—	151,500	—	$28.5M
MRKMerck & Co Inc	2.6%	—	213,500	—	$27.4M
LLYEli Lilly & Co	2.5%	3.8%	22,315	-33.8%	$26.8M
ABBVAbbvie Inc	2.3%	1.9%	96,775	+35.2%	$24.4M
ALHCAlignment Healthcare Inc	2.2%	2.3%	997,083	-5.4%	$23.7M
EWEdwards Lifesciences Corp	2.2%	1.6%	260,000	+59.5%	$23.5M
GILDGilead Sciences Inc	2.1%	2.9%	178,250	+6.3%	$22.5M
JAZZJazz Pharmaceuticals PLC	2.0%	1.8%	87,440	+15.2%	$21.1M
BIIBBiogen Inc	1.9%	2.5%	94,850	-13.1%	$20.5M
SYKStryker Corporation	1.9%	1.9%	65,000	+36.0%	$20.5M
BSXBoston Scientific Corp	1.8%	4.8%	450,500	-27.9%	$19.2M
JNJJohnson & Johnson	1.7%	—	72,500	—	$18.4M
GHGuardant Health Inc	1.6%	1.7%	115,000	-20.7%	$17.3M
REGNRegeneron Pharmaceuticals	1.6%	4.6%	27,390	-43.1%	$17.1M
GKOSGlaukos Corp	1.6%	1.1%	119,000	+41.7%	$16.6M
BMRNBiomarin Pharmaceutical Inc	1.6%	1.4%	290,500	+40.3%	$16.6M
NRIXNurix Therapeutics Inc	1.6%	—	684,250	—	$16.6M
NTRANatera Inc	1.6%	1.3%	61,050	+18.3%	$16.6M
MIRMMirum Pharmaceuticals Inc	1.5%	1.1%	139,205	+50.3%	$16.3M
INSMInsmed Inc	1.5%	3.2%	151,960	-4.9%	$16.2M
THCTenet Healthcare Corp	1.5%	1.3%	85,200	+57.8%	$15.9M
TMOThermo Fisher Scientific Inc	1.5%	2.5%	31,580	-23.6%	$15.8M
CNCCentene Corp Del	1.5%	—	244,000	—	$15.7M
AXSMAxsome Therapeutics, Inc.	1.5%	1.3%	63,050	-1.2%	$15.4M
DHRDanaher Corp Del	1.4%	—	80,252	—	$15.3M
VRTXVertex Pharmaceuticals Inc	1.4%	2.4%	30,685	-29.4%	$15.2M
AVRAnteris Technologies Global	1.4%	1.0%	1,538,625	+7.0%	$15.2M
NBIXNeurocrine Biosciences Inc	1.4%	1.6%	85,841	-14.9%	$14.5M
PNTGPennant Group Inc	1.3%	1.0%	371,471	+34.9%	$13.7M
ISRGIntuitive Surgical Inc	1.3%	2.1%	34,500	-6.4%	$13.7M
ELVElevance Health Inc Formerly	1.3%	1.2%	34,900	+8.0%	$13.5M
LIVNLivanova PLC	1.3%	1.2%	164,000	+5.8%	$13.5M
CORCencora Inc	1.2%	2.0%	46,778	-10.7%	$13.2M
CRLCharles Riv Labs Intl Inc	1.2%	—	57,200	—	$13.0M
IDYAIdeaya Biosciences Inc	1.2%	1.1%	343,800	+34.6%	$12.8M
MCKMckesson Corp	1.2%	1.8%	16,550	-1.8%	$12.5M
SNDXSyndax Pharmaceuticals Inc	1.2%	1.1%	560,250	+47.7%	$12.2M
BTSGBrightspring Health Services I	1.1%	—	165,896	—	$11.6M
MDTMedtronic PLC	1.1%	1.0%	145,000	+61.1%	$11.3M
MLYSMineralys Therapeutics Inc	1.1%	0.9%	416,371	+58.3%	$11.2M
OSCROscar Health, Inc.	1.1%	0.9%	392,000	-40.6%	$11.2M
RPRXRoyalty Pharma PLC	1.0%	1.4%	197,000	-15.5%	$11.0M
DXCMDexcom Inc	1.0%	—	160,000	—	$10.8M
ALGNAlign Technology Inc	1.0%	—	63,000	—	$10.6M
SYRESpyre Therapeutics	1.0%	—	119,300	—	$10.6M
RLAYRelay Therapeutics Inc	1.0%	—	566,000	—	$10.6M
ARWRArrowhead Pharmaceuticals in	1.0%	1.1%	128,000	-11.4%	$10.4M
AAgilent Technologies Inc	0.9%	—	75,000	—	$10.0M

What Rhenman & Partners Asset Management AB bought and sold in Q2 2026, against Q1 2026.

New positions

Q1 2026's filing was too long to tell new positions apart.

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: +21.6% /yr; S&P 500 +20.1%
3 years: +8.9% /yr; S&P 500 +20.4%
5 years: +10.0% /yr; S&P 500 +11.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$1.1B	99
Q1 2026	$810.5M	86
Q4 2025	$1.1B	94
Q3 2025	$903.7M	92
Q2 2025	$791.0M	90
Q1 2025	$870.0M	94
Q4 2024	$972.9M	92
Q3 2024	$1.2B	95
Q2 2024	$1.0B	93
Q1 2024	$1.1B	84
Q4 2023	$1.0B	85
Q3 2023	$927.5M	85

Questions about Rhenman & Partners Asset Management AB's portfolio

What stocks does Rhenman & Partners Asset Management AB own?

Rhenman & Partners Asset Management AB's latest 13F, for Q2 2026 and filed Aug 13, 2026, lists 99 positions worth $1.1B. The largest are Unitedhealth Group Inc (UNH) at 3.7%, Cvs Health Corp (CVS) at 2.7%, Astrazeneca PLC (AZN) at 2.7%, Merck & Co Inc (MRK) at 2.6% and Eli Lilly & Co (LLY) at 2.5%.

What did Rhenman & Partners Asset Management AB buy last quarter?

In Q2 2026, Rhenman & Partners Asset Management AB added Unitedhealth Group Inc (UNH) (+105.7% shares), Medtronic PLC (MDT) (+61.1% shares) and Edwards Lifesciences Corp (EW) (+59.5% shares), compared with its Q1 2026 filing.

What did Rhenman & Partners Asset Management AB sell last quarter?

In Q2 2026, Rhenman & Partners Asset Management AB cut from its top 50 Veeva Sys Inc (VEEV), cut from its top 50 Madrigal Pharmaceuticals Inc (MDGL), cut from its top 50 Procept Biorobotics Corp (PRCT), cut from its top 50 Abbott Laboratories (ABT), cut from its top 50 Alnylam Pharmaceuticals Inc (ALNY), Regeneron Pharmaceuticals (REGN) (-43.1% shares), Oscar Health, Inc. (OSCR) (-40.6% shares) and Eli Lilly & Co (LLY) (-33.8% shares), compared with its Q1 2026 filing.

How has Rhenman & Partners Asset Management AB's portfolio performed?

A portfolio copying Rhenman & Partners Asset Management AB's 20 largest 13F holdings each quarter, from the day each filing was public, returned +8.9% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +21.6% against +20.1%. Over 5 years: +10.0% a year against +11.6%.

When is Rhenman & Partners Asset Management AB's next 13F filing due?

13F filings are due 45 days after each quarter ends. Rhenman & Partners Asset Management AB's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.